2026 Ultan McDermott: Biology and Biochemistry Researcher – H-Index, Publications & Awards

Discipline name	D-Index	World Ranking	Current World Ranking	National Ranking	Current National Ranking	Publications	Citations
Biology and Biochemistry	75	5179	4784	395	365	221	54167

Overview

Ultan McDermott is a researcher affiliated with AstraZeneca in the United Kingdom, focusing primarily on the fields of Biochemistry, Genetics and Molecular Biology as well as Medicine. Their work spans molecular biology, cancer research, oncology, genetics, and computational theory and mathematics.

Their research concentrates on the following main topics:

Cancer Genomics and Diagnostics
Computational Drug Discovery Methods
Colorectal Cancer Treatments and Studies
CRISPR and Genetic Engineering
Lung Cancer Treatments and Mutations
Radiomics and Machine Learning in Medical Imaging
Protein Degradation and Inhibitors

McDermott has published extensively in venues including Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), Science Translational Medicine, Nature Communications, and Communications Biology.

Frequent co-authors collaborating with McDermott include:

Matthias Pfeifer (9 publications)
Mathew J. Garnett (8 publications)
Aikaterini Chatzipli (7 publications)
Stacey Price (7 publications)
Enric Domingo (6 publications)

Some notable recent research papers authored or co-authored by McDermott are:

"Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning", 2020, Gut
"ctDNA monitoring using patient-specific sequencing and integration of variant reads", 2020, Science Translational Medicine
"A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components", 2020, Science Translational Medicine
"Knowledge graph-based recommendation framework identifies drivers of resistance in EGFR mutant non-small cell lung cancer", 2022, Nature Communications
"Genome-wide CRISPR screens of oral squamous cell carcinoma reveal fitness genes in the Hippo pathway", 2020, eLife

Best Publications

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov;Serena Nik-Zainal;Serena Nik-Zainal;David C. Wedge;Samuel A. J. R. Aparicio

10789
Citations
Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells

Wanjuan Yang;Jorge Soares;Patricia Greninger;Elena J. Edelman

3321
Citations
Pan-cancer analysis of whole genomes

Peter J. Campbell;Gad Getz;Jan O. Korbel;Joshua M. Stuart

3090
Citations
Systematic identification of genomic markers of drug sensitivity in cancer cells

Mathew J. Garnett;Elena J. Edelman;Sonja J. Heidorn;Christopher Greenman;Christopher Greenman

2736
Citations
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations

Sreenath V. Sharma;Diana Y. Lee;Bihua Li;Margaret P. Quinlan

2688
Citations
COSMIC: exploring the world's knowledge of somatic mutations in human cancer

Simon A. Forbes;David Beare;Prasad Gunasekaran;Kenric Leung

2599
Citations
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients

Marc van de Wetering;Hayley E. Francies;Joshua M. Francis;Joshua M. Francis;Gergana Bounova

2432
Citations
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

2340
Citations
A Landscape of Pharmacogenomic Interactions in Cancer

Francesco Iorio;Francesco Iorio;Theo A. Knijnenburg;Theo A. Knijnenburg;Daniel J. Vis;Graham R. Bignell

2122
Citations
The evolutionary history of lethal metastatic prostate cancer.

Gunes Gundem;Peter Van Loo;Peter Van Loo;Peter Van Loo;Barbara Kremeyer;Ludmil B. Alexandrov

1450
Citations
Patterns of somatic structural variation in human cancer genomes

Yilong Li;Nicola D Roberts;Jeremiah A Wala;Jeremiah A Wala;Ofer Shapira;Ofer Shapira

942
Citations
A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

Konstantinos Tzelepis;Hiroko Koike-Yusa;Etienne De Braekeleer;Yilong Li

783
Citations
Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition

Alexandre Puissant;Stacey M. Frumm;Gabriela Alexe;Christopher F. Bassil

686
Citations
Low MITF/AXL ratio predicts early resistance to multiple targeted drugs in melanoma.

Judith Müller;Oscar Krijgsman;Jennifer Tsoi;Lidia Robert

632
Citations
Elevated CRAF as a Potential Mechanism of Acquired Resistance to BRAF Inhibition in Melanoma

Clara Montagut;Sreenath V. Sharma;Toshi Shioda;Ultan McDermott

605
Citations
Machine Learning Prediction of Cancer Cell Sensitivity to Drugs Based on Genomic and Chemical Properties

Michael P. Menden;Francesco Iorio;Francesco Iorio;Mathew Garnett;Ultan McDermott

593
Citations
Pharmacogenomic agreement between two cancer cell line data sets

Nicolas Stransky;Mahmoud Ghandi

538
Citations
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling.

Sidong Huang;Michael Hölzel;Theo Knijnenburg;Andreas Schlicker

512
Citations
Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors

Ultan McDermott;A. John Iafrate;Nathanael S. Gray;Toshi Shioda

505
Citations
The evolutionary history of lethal metastatic prostate cancer

G Gundem;P Van Loo;B Kremeyer;L B Alexandrov

5
Citations